NEW YORK, NY, Aug 9, 2022 - (ACN Newswire via SEAPRWire.com) - PCG Digital -- Life may change for the better for the 10 million Americans suffering from fibromyalgia. The development-stage biotech Virios Therapeutics, Inc. (Nasdaq:VIRI) is anticipating the reporting of phase 2b treatment results for its lead fibromyalgia treatment candidate this September and continues to add value through its research and development of compelling clinical assets for multiple categories of viruses.Virios Therapeutics, Inc.Humans and viral pathogens have co-existed for millennia. Some human viruses are gone as quickly as they came, while others - such as the herpes virus - are able to co-exist with a human's immune system, leaving genetic material permanently in the host's cells.Nearly four billion people around the world are infected with herpes viruses. Most of us don't even know if we are infected and the virus may remain dormant in the body for months or years before reactivating in response to stress.Dr. William Pridgen, the founder of Virios Therapeutics, Inc. has observed the effects of virus reactivation firsthand. In 2002, he noted recurring functional gastrointestinal disorder symptoms ("...